Official ESCRS | European Society of Cataract & Refractive Surgeons
Barcelona 2015 Programme Registration Glaucoma Day 2015 Exhibition Virtual Exhibition Satellite Meetings Hotel Booking Star Alliance
ISTANBUL escrs









Take a look inside the London 2014 Congress

video-icon

Then register to join us
in Barcelona!





Pneumodescemetopexy for Descemet's membrane detachment after phacoemulsification

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Session Details

Session Title: Presented Poster Session: Cataract Surgery Complications and Management III

Session Date/Time: Sunday 06/09/2015 | 09:30-11:00

Paper Time: 09:30

Venue: Poster Village: Pod 1

First Author: : C.Fan HONG KONG

Co Author(s): :    C. Liu   T. Leung           

Abstract Details

Purpose:

To evaluate the functional and anatomical outcomes of pneumodescemetopexy for descemet's membrane detachment (DMD) after phacoemulsification, and to determine prognostic factors associated with procedure failure

Setting:

Department of Ophthalmology, United Christian Hospital, Hong Kong

Methods:

Retrospective study of 29 eyes from 29 patients who underwent pneumodescemetopexy for DMD after phacoemulsification. 19 patients underwent pneumodescemetopexy during phacoemulsification and 10 patients underwent pneumodescemetopexy as second operation.

Results:

All eyes (100%) had descemet's membrane re-attached with corneal oedema resolved at final visit (18 eyes required 1 pneumodescemetopexy, 8 eyes required 2 pneumodescemetopexies, and 3 eyes required 3 pneumodescemetopexies). The visual acuity improved from 0.95 logMAR units to 0.39 logMAR units at final visit (p less than 0.001). The risk factors for requiring more than 1 pneumodescemetopexy to re-attach descemet's membrane included: not performing pneumodescemetopexy during phacoemulsification (odd ratio=10.0, P=0.045), and central corneal involvement by DMD (odd ratio=9.0, P=0.018).

Conclusions:

Pneumodescemetopexy is an effective treatment for DMD after phacoemulsification with good anatomical and functional outcomes.

Financial Interest:

NONE

Back to previous